LEMTRADA (Genzyme Corporation)


Welcome to the PulseAid listing for the LEMTRADA drug offered from Genzyme Corporation. This CD52-directed Antibody Interactions [MoA],CD52-directed Cytolytic Antibody [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Genzyme Corporation
NON-PROPRIETARY NAME: ALEMTUZUMAB
SUBSTANCE NAME: ALEMTUZUMAB
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: CD52-directed Antibody Interactions [MoA],CD52-directed Cytolytic Antibody [EPC]
ROUTE: INTRAVENOUS
DOSAGE FORM: INJECTION, SOLUTION, CONCENTRATE
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2014-11-18
END MARKETING DATE: 0000-00-00


LEMTRADA HUMAN PRESCRIPTION DRUG Details:

Item DescriptionLEMTRADA from Genzyme Corporation
LABELER NAME: Genzyme Corporation
DEA SCHEDULE:
ACTIVE STRENGTH: 12(mg/1.2mL)
START MARKETING DATE: 2014-11-18
END MARKETING DATE: 0000-00-00
PRODUCT ID: 58468-0200_347e46f8-486d-4626-ac47-5916d5bb3d4d
PRODUCT NDC: 58468-0200
APPLICATION NUMBER: BLA103948

Other ALEMTUZUMAB Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Genzyme CorporationLEMTRADA